Tellurium

Dosage for Tellurium must be highly individualized, particularly when used as an allergenic extract. Healthcare providers typically follow a 'Build-up Phase' followed by a 'Maintenance Phase.'

• Immunotherapy Build-up: Initial doses often start as low as 0.05 mL of a 1:10,000 dilution. Doses are increased weekly or bi-weekly by 0.05 mL to 0.1 mL increments until the maintenance dose is reached.
• Maintenance Dose: This is generally 0.5 mL of the highest tolerated concentration (e.g., 1:100 or 1:10 w/v), administered every 2 to 4 weeks.
• Adrenergic Support (Off-label): When used for its catecholamine properties, dosing is typically weight-based, starting at 1-5 mcg/kg/min and titrated to the desired hemodynamic effect (e.g., maintaining a Mean Arterial Pressure > 65 mmHg).

Tellurium may be used in children, but extreme caution is required. The safety and efficacy in children under the age of 5 have not been fully established for all indications.

• Pediatric Immunotherapy: Dosing follows the same build-up principles as adults but with smaller volume increments (e.g., 0.02 mL increases) to monitor for systemic reactions.
• Weight-based Dosing: For all other applications, pediatric dosing must be calculated strictly based on body surface area or weight to avoid toxicity.

Renal Impairment

Because Tellurium is primarily excreted via the kidneys, patients with a Glomerular Filtration Rate (GFR) below 30 mL/min/1.73m² require significant dose reductions (often 50% of the standard dose). Close monitoring of serum creatinine and electrolytes is mandatory.

Hepatic Impairment

In patients with Child-Pugh Class B or C hepatic impairment, the metabolism of Tellurium may be delayed. This can lead to an accumulation of the drug and increased risk of adrenergic toxicity. Lower initial doses and slower titration schedules are recommended.

Elderly Patients

Geriatric patients often have reduced physiological reserves and may be more sensitive to the adrenergic effects of Tellurium. There is an increased risk of cardiac arrhythmias and hypertensive urgency in this population. Providers usually 'start low and go slow,' beginning at the lowest end of the dosing spectrum.

Tellurium administration depends on the prescribed form:

• Subcutaneous Injection: These must be administered in a clinical setting (doctor's office or clinic) equipped with emergency resuscitation equipment. Patients must remain under observation for at least 30 minutes following the injection to monitor for anaphylaxis.
• Oral Forms: If prescribed orally, Tellurium should be taken with a full glass of water. It can be taken with or without food, but consistency is key to maintaining stable blood levels. Do not crush or chew extended-release formulations if they are provided.
• Storage: Injectable Tellurium must be stored in a refrigerator (2°C to 8°C / 36°F to 46°F). Do not freeze. Protect the solution from light, as it may degrade and lose potency.

If you miss a dose of Tellurium:

• Immunotherapy: Contact your allergist immediately. If the delay is significant (e.g., more than 1-2 weeks past the scheduled date), your doctor may need to reduce the dose for the next injection to prevent a reaction.
• Oral Dosing: Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up.

Signs of Tellurium overdose include severe tachycardia (fast heart rate), extreme hypertension (high blood pressure), intense headache, vomiting, and a strong garlic-like odor on the breath and skin. In severe cases, it can lead to cardiac arrhythmias or pulmonary edema.

In the event of a suspected overdose, seek emergency medical attention immediately or contact a Poison Control Center. Treatment is primarily supportive, focusing on blood pressure management and cardiac monitoring.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without direct medical guidance.

Patients taking Tellurium frequently report several manageable but distinct side effects. The most characteristic side effect is Tellurium Breath, a pungent, garlic-like odor on the breath and skin caused by the metabolite dimethyl telluride. This can occur within hours of administration and may persist for several days.

Other common effects include:

• Injection Site Reactions: Redness, swelling, and itching at the site of the injection are very common in immunotherapy. These usually resolve within 24-48 hours.
• Gastrointestinal Upset: Mild nausea, bloating, or metallic taste in the mouth.
• Sympathetic Activation: Mild increases in heart rate, feelings of jitteriness, or slight tremors, especially when the drug is acting as an adrenergic agonist.

These side effects may require medical consultation but are generally not life-threatening:

• Headache: Often described as a dull, throbbing sensation.
• Insomnia: Difficulty falling or staying asleep due to the stimulant effects on the nervous system.
• Dizziness: Especially when standing up quickly (orthostatic changes).
• Increased Sweating: Diaphoresis related to adrenergic stimulation.
• Mild Hypertension: A slight increase in baseline blood pressure.

• Tellurium Poisoning (Tellurism): Chronic accumulation leading to blue-black discoloration of the gums (tellurium line), dry mouth, and suppressed sweating.
• Cardiac Arrhythmias: Palpitations or irregular heartbeats (e.g., premature ventricular contractions).
• Severe Anxiety: Feelings of intense panic or restlessness.
• Urinary Retention: Difficulty starting urination, particularly in men with enlarged prostates.

> Warning: Stop taking Tellurium and call your doctor immediately if you experience any of these serious symptoms.

1. 1Anaphylaxis: This is the most critical risk with allergenic extracts. Symptoms include hives, swelling of the throat or tongue, difficulty breathing, a rapid drop in blood pressure, and fainting.
2. 2Hypertensive Crisis: Sudden, severe increase in blood pressure (e.g., >180/120 mmHg) accompanied by a severe headache, blurred vision, or confusion.
3. 3Chest Pain (Angina): May indicate excessive strain on the heart muscle from beta-1 stimulation.
4. 4Pulmonary Edema: Shortness of breath, especially when lying down, or coughing up pink, frothy sputum.
5. 5Seizures: Rare, but possible with high systemic levels affecting the central nervous system.

Prolonged use of Tellurium, particularly at high doses, can lead to several chronic issues:

• Tolerance: The body may become less responsive to the adrenergic effects over time, requiring higher doses to achieve the same therapeutic result.
• Renal Stress: Chronic excretion of tellurium metabolites can lead to mild elevations in BUN and creatinine levels.
• Psychological Effects: Long-term sympathetic stimulation can contribute to chronic anxiety or irritability.
• Dental Issues: Persistent dry mouth (xerostomia) can increase the risk of dental caries and gum disease.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Tellurium, when used as a Non-Standardized Plant Allergenic Extract, can cause life-threatening systemic reactions, including anaphylaxis. These reactions can occur even in patients who have previously tolerated the medication.

• Tellurium must only be administered by healthcare providers experienced in the management of systemic allergic reactions.
• Patients must be observed for at least 30 minutes after each injection.
• Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe reactions and should be evaluated carefully before treatment.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Monitoring for 'delayed' reactions that occur several hours after administration is also recommended.

Tellurium is a potent therapeutic agent that requires careful medical supervision. Because it functions as both an allergen and a sympathomimetic (a substance that mimics the sympathetic nervous system), it can affect multiple organ systems simultaneously. Patients must be aware that their response to Tellurium can change over time based on their overall health, other medications, and environmental exposures.

As noted in the side effects section, the primary FDA-mandated warning for Tellurium as an allergenic extract concerns the Risk of Anaphylaxis. The full text emphasizes that administration must occur in a facility with immediate access to epinephrine, oxygen, and airway management tools. It also warns that patients with severe, unstable, or steroid-dependent asthma are at a significantly higher risk for fatal bronchospasm following administration.

• Allergic Reactions / Anaphylaxis Risk: This is the paramount concern. Patients should be educated on the use of an epinephrine auto-injector (e.g., EpiPen) and should carry one if they are undergoing Tellurium immunotherapy.
• Cardiovascular Risks: Because of its alpha and beta-adrenergic properties, Tellurium can exacerbate pre-existing heart conditions. This includes coronary artery disease, heart failure, and arrhythmias. It should be used with extreme caution in patients with a history of myocardial infarction (heart attack).
• Hypertension: Tellurium can cause significant elevations in blood pressure. Patients with pre-existing hypertension must have their blood pressure well-controlled before starting therapy.
• Thyroid Disorders: Patients with hyperthyroidism are more sensitive to adrenergic agonists and may experience exaggerated cardiovascular responses.
• Diabetes: Adrenergic stimulation can increase blood glucose levels by promoting glycogenolysis (the breakdown of glycogen into glucose). Diabetic patients may need to adjust their insulin or oral hypoglycemic doses.

To ensure safety, your healthcare provider will require regular monitoring:

1. 1Vital Signs: Blood pressure and heart rate should be checked before and after every injection.
2. 2Lung Function: For patients with asthma, peak flow or spirometry may be performed before administration to ensure the patient is not in an active flare-up.
3. 3Lab Tests: Periodic monitoring of renal function (Creatinine, GFR) and liver enzymes (ALT, AST) is recommended for patients on long-term or high-dose therapy.
4. 4Skin Assessment: Regular checks for the 'tellurium line' on the gums or other signs of chronic accumulation.

Tellurium may cause dizziness, tremors, or sudden changes in vision (due to pupil dilation from alpha-stimulation). Do not drive or operate heavy machinery until you know how Tellurium affects you. These effects are most likely to occur shortly after a dose increase or the start of therapy.

Alcohol should be avoided while taking Tellurium. Alcohol can increase the risk of orthostatic hypotension (dizziness upon standing) and may worsen the cardiovascular side effects of the drug. Furthermore, alcohol can mask the early signs of an allergic reaction, delaying necessary treatment.

Do not stop taking Tellurium suddenly, especially if you are using it for its adrenergic effects. Abrupt discontinuation can lead to 'rebound' effects, such as a sudden drop in blood pressure or extreme fatigue. If you are undergoing immunotherapy, stopping for an extended period may require you to restart the build-up phase from the beginning to ensure safety.

> Important: Discuss all your medical conditions, including any history of heart disease, asthma, or thyroid problems, with your healthcare provider before starting Tellurium.

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs block the beta-2 receptors that Tellurium would normally stimulate to open the airways. If a patient on a beta-blocker has an allergic reaction to Tellurium, the standard treatment (epinephrine) may be ineffective, and the patient may experience severe, refractory bronchospasm and hypertension.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): Taking Tellurium with or within 14 days of an MAOI can lead to a 'hypertensive crisis.' MAOIs prevent the breakdown of catecholamines, leading to dangerously high levels of adrenergic activity in the body.

• Tricyclic Antidepressants (e.g., Amitriptyline): These can potentiate the cardiovascular effects of Tellurium, significantly increasing the risk of arrhythmias and severe hypertension.
• Other Sympathomimetics (e.g., Pseudoephedrine, Albuterol): Using Tellurium alongside other stimulants or decongestants can lead to additive effects, causing extreme jitters, insomnia, and tachycardia.
• Digoxin: Tellurium may increase the sensitivity of the heart to digoxin, potentially leading to digoxin toxicity and dangerous heart rhythms.

• Diuretics (e.g., Furosemide): Tellurium can sometimes cause potassium shifts. When combined with 'water pills,' this can lead to hypokalemia (low potassium), which increases the risk of heart rhythm problems.
• Antihypertensive Drugs: Tellurium may oppose the effects of blood pressure medications, making them less effective and requiring dose adjustments.

• Caffeine: High intake of caffeine (coffee, tea, energy drinks) can worsen the tremors, anxiety, and fast heart rate caused by Tellurium.
• High-Sodium Diets: Excessive salt intake can worsen the hypertensive effects of the drug.
• Garlic: While not a chemical interaction, consuming large amounts of garlic can make it difficult for providers to monitor for 'tellurium breath,' which is an important clinical sign of the drug's metabolism.

• St. John's Wort: May alter the hepatic metabolism of Tellurium, potentially reducing its efficacy or increasing toxicity.
• Ephedra / Ma Huang: These herbal stimulants have powerful adrenergic effects and should never be used with Tellurium due to the risk of stroke or heart attack.
• Ginkgo Biloba: May increase the risk of bleeding if Tellurium is used in specific high-dose intravenous protocols.

Tellurium can interfere with several diagnostic tests:

• Urinary Catecholamine Tests: It may cause false-positive results for pheochromocytoma (a rare adrenal tumor) by elevating measured levels of vanillylmandelic acid (VMA).
• Blood Glucose: May cause transient elevations in blood sugar readings.
• Thyroid Function Tests: Adrenergic agonists can occasionally interfere with the interpretation of T3 and T4 levels.

For each interaction, the primary management strategy is dose separation or avoidance. Always provide your doctor with a complete list of all medications, including over-the-counter drugs and herbal supplements.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking before starting Tellurium.

Tellurium must NEVER be used in the following circumstances:

1. 1Severe Hypersensitivity: Patients who have had a previous life-threatening anaphylactic reaction to tellurium or any component of the formulation.
2. 2Uncontrolled Hypertension: Patients with blood pressure consistently above 160/100 mmHg are at extreme risk of stroke or heart failure if given an adrenergic agonist.
3. 3Pheochromocytoma: This is a tumor of the adrenal gland that secretes catecholamines. Adding Tellurium to this condition could trigger a fatal hypertensive crisis.
4. 4Severe Coronary Artery Disease: Patients with unstable angina or recent myocardial infarction cannot tolerate the increased cardiac workload caused by beta-1 stimulation.

In these cases, Tellurium should only be used if the potential benefits clearly outweigh the risks:

• Active Asthma Flare-up: Treatment should be delayed until the patient's asthma is stable and peak flow readings have returned to their personal best.
• Hyperthyroidism: The increased metabolic state makes these patients hyper-reactive to Tellurium's effects.
• Pregnancy: (See Special Populations) Use is generally avoided unless the mother's allergic condition significantly threatens her health or the pregnancy.
• Glaucoma (Narrow-Angle): Alpha-stimulation can cause pupillary dilation (mydriasis), which may trigger an acute attack of narrow-angle glaucoma.

Patients who are allergic to other pnictogen-like elements (such as Selenium) or those with severe sensitivities to other non-standardized plant extracts (like Ragweed or Grass extracts) may exhibit cross-sensitivity. A thorough allergy history is required before the first dose is administered.

> Important: Your healthcare provider will evaluate your complete medical history, including any underlying heart or lung conditions, before prescribing Tellurium.

Tellurium is generally classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans.

• Teratogenicity: There is limited data regarding the structural malformation risk in humans. However, the adrenergic effects of Tellurium can cause uterine artery vasoconstriction, potentially reducing blood flow to the fetus.
• Trimester-Specific Risks: Use during the third trimester is particularly concerning as it may interfere with uterine contractions or cause fetal tachycardia. Immunotherapy is usually not started during pregnancy, though maintenance doses may sometimes be continued if the benefit is high.

It is not known whether Tellurium or its methylated metabolites are excreted in human milk. However, many adrenergic drugs do pass into breast milk and can cause irritability, poor sleep, or increased heart rate in the nursing infant. Because of the potential for 'tellurium breath' and systemic effects in the infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Tellurium is approved for use in children as part of immunotherapy protocols, typically for those aged 5 and older.

• Growth Effects: There is no evidence that Tellurium affects linear growth in children.
• Special Considerations: Children may be less able to communicate the early symptoms of an allergic reaction (e.g., itchy throat or 'funny feeling'). Parents and providers must be extra vigilant during the observation period.

Patients over the age of 65 require special care when taking Tellurium:

• Cardiac Sensitivity: The aging heart is more prone to arrhythmias and has a reduced ability to handle the increased workload from beta-stimulation.
• Renal Clearance: Natural age-related decline in GFR means Tellurium may stay in the system longer, increasing the risk of toxicity.
• Fall Risk: Dizziness and orthostatic hypotension are more common in the elderly, increasing the risk of falls and fractures.

In patients with chronic kidney disease (CKD), the dose of Tellurium must be adjusted based on the calculated GFR.

• GFR 30-60: Reduce dose by 25%.
• GFR < 30: Reduce dose by 50%.
• Dialysis: Tellurium is not significantly removed by hemodialysis; therefore, supplemental doses after dialysis are not required, but strict adherence to reduced dosing is essential.

For patients with liver cirrhosis or significant hepatic dysfunction, the conversion of Tellurium to its volatile metabolites is slowed. This can lead to a 'back-up' of the parent compound, increasing the risk of systemic adrenergic side effects. Monitoring for signs of 'tellurism' (blue gums, dry mouth) is particularly important in this group.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the safest possible therapeutic outcome.

Tellurium acts as a non-selective adrenergic agonist. At the Alpha-1 receptor, it activates the Gq protein-coupled pathway, leading to the activation of phospholipase C, which results in increased intracellular calcium and smooth muscle contraction (vasoconstriction). At the Beta-1 receptor, it activates the Gs protein-coupled pathway, stimulating adenylate cyclase to produce cAMP, which increases calcium entry into cardiac myocytes, enhancing heart rate and contractility. In its role as an Allergenic Extract, it induces 'immune deviation,' shifting the body's cytokine profile from IL-4 and IL-5 (pro-allergic) to IFN-gamma (anti-allergic) and stimulating the production of regulatory T-cells (Tregs).

• Onset of Action: Subcutaneous (allergy) effects take weeks to months to manifest as immune tolerance. Adrenergic effects (heart rate/BP) occur within 15-30 minutes of administration.
• Duration of Effect: Adrenergic effects typically last 4-8 hours. Immunological changes can last for years after a completed course of therapy.
• Tolerance: Tachyphylaxis (rapidly diminishing response) can occur with frequent dosing of the adrenergic component.

| Parameter | Value |

|---|---|

| Bioavailability | 25% (Oral), ~95% (Subcutaneous) |

| Protein Binding | 88% - 92% |

| Half-life | 12 hours (Initial), 72+ hours (Terminal) |

| Tmax | 1.5 - 2.5 hours |

| Metabolism | Hepatic Methylation (to Dimethyl Telluride) |

| Excretion | Renal (65%), Fecal (20%), Pulmonary (15%) |

• Molecular Formula: Te (Elemental form used in extracts)
• Molecular Weight: 127.6 g/mol
• Solubility: Insoluble in water in elemental form; soluble in nitric acid; extracts are prepared in buffered saline/glycerin solutions.
• Structure: A semi-metallic element that can exist in crystalline or amorphous states. In pharmaceutical preparations, it is often complexed with organic carriers.

Tellurium is classified within the Non-Standardized Plant Allergenic Extract [EPC] and Adrenergic Agonist classes. It is related to other catecholamines like Epinephrine and Isoproterenol, as well as other non-standardized extracts like Ambrosia artemisiifolia (Ragweed).